{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T23:14:50Z","timestamp":1740179690176,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T00:00:00Z","timestamp":1714262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T00:00:00Z","timestamp":1714262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>In 2013, rituximab was approved in France for the treatment of ANCA-associated vasculitis (AAV). The aim of the study was to compare the treatment and health events of adult incident patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), included before rituximab approval (over 2010\u20132012, Group 1) and those included after rituximab approval (over 2014\u20132017, Group 2).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>Data were extracted from the French National Health Insurance database (SNDS) including outpatient health care consumption and hospital discharge forms. Comparisons between inclusion periods were performed using Wilcoxon and \u03c7\u00b2 tests. Kaplan-Meier method was used to model the duration of treatment induction, maintenance, and off-drug periods. Fine and Gray tests were used to compare treatment phase durations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 694 GPA and 283 MPA patients were included in Group 1, while 668 GPA and 463 MPA patients were included in Group 2. Between the two inclusion periods, the proportions of patients treated with rituximab increased in the induction and maintenance phases whereas treatment with azathioprine declined. These proportions remained stable in the case of methotrexate, cyclophosphamide, and glucocorticoid-treated patients. Frequency of first-time hospitalized infections, diabetes and renal failure during the first year after inclusion increased for both groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Limitations of the study<\/jats:title>\n                <jats:p>This is a retrospective study based on claims data including only 76% of people covered by health insurance in France. The period studied includes the learning phase of using rituximab. This study lacks biological data and precise quantitative analysis for the use of steroids, therefore the criteria for establishing diagnosis and therapeutic choice were unknown.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Introduction of rituximab reduced the use of azathioprine without affecting the use of glucocorticoids or cyclophosphamide.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41927-024-00385-8","type":"journal-article","created":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T05:01:37Z","timestamp":1714280497000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evolution of therapeutic management of patients with ANCA associated vasculitis in France after licensing Rituximab use"],"prefix":"10.1186","volume":"8","author":[{"given":"C\u00e9cile-Audrey","family":"Durel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric Simon","family":"Thervet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Chauveau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3291-4328","authenticated-orcid":false,"given":"Aur\u00e9lie","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6612-7336","authenticated-orcid":false,"given":"Benjamin","family":"Terrier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre M","family":"Bataille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,28]]},"reference":[{"key":"385_CR1","doi-asserted-by":"publisher","first-page":"102910","DOI":"10.1016\/j.jaut.2022.102910","volume":"133","author":"PM Bataille","year":"2022","unstructured":"Bataille PM, Durel C-A, Chauveau D, et al. Epidemiology of granulomatosis with polyangiitis and microscopic polyangiitis in adults in France. J Autoimmun. 2022;133:102910. https:\/\/doi.org\/10.1016\/j.jaut.2022.102910.","journal-title":"J Autoimmun"},{"key":"385_CR2","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s13023-020-01621-3","volume":"15","author":"B Terrier","year":"2020","unstructured":"Terrier B, Darbon R, Durel C-A, et al. French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides). Orphanet J Rare Dis. 2020;15:351. https:\/\/doi.org\/10.1186\/s13023-020-01621-3.","journal-title":"Orphanet J Rare Dis"},{"key":"385_CR3","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1053\/j.ajkd.2019.04.031","volume":"75","author":"D Geetha","year":"2020","unstructured":"Geetha D, Jefferson JA. ANCA-Associated Vasculitis: Core Curriculum 2020. Am J Kidney Dis. 2020;75:124\u201337. https:\/\/doi.org\/10.1053\/j.ajkd.2019.04.031.","journal-title":"Am J Kidney Dis"},{"key":"385_CR4","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/rheumatology\/keu366","volume":"54","author":"J Robson","year":"2015","unstructured":"Robson J, Doll H, Suppiah R, et al. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology. 2015;54:471\u201381. https:\/\/doi.org\/10.1093\/rheumatology\/keu366.","journal-title":"Rheumatology"},{"key":"385_CR5","doi-asserted-by":"publisher","first-page":"S267","DOI":"10.37765\/ajmc.2021.88746","volume":"27","author":"CL Koening","year":"2021","unstructured":"Koening CL, von Hennigs I. Antineutrophil cytoplasmic antibody (ANCA) vasculitis: pathophysiology, diagnosis, and the evolving treatment landscape. Am J Manag Care. 2021;27:S267\u201376. https:\/\/doi.org\/10.37765\/ajmc.2021.88746.","journal-title":"Am J Manag Care"},{"key":"385_CR6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, et al. Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. N Engl J Med. 2010;363:221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa0909905.","journal-title":"N Engl J Med"},{"key":"385_CR7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909169","author":"RB Jones","year":"2010","unstructured":"Jones RB, Cohen Tervaert JW, Hauser T, et al. Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis. N Engl J Med. 2010. https:\/\/doi.org\/10.1056\/NEJMoa0909169.","journal-title":"N Engl J Med"},{"key":"385_CR8","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1002\/acr.24332","volume":"73","author":"PA Merkel","year":"2021","unstructured":"Merkel PA, Niles JL, Mertz LE, et al. Long-term safety of Rituximab in Granulomatosis with Polyangiitis and in microscopic polyangiitis. Arthritis Care Res. 2021;73:1372\u20138. https:\/\/doi.org\/10.1002\/acr.24332.","journal-title":"Arthritis Care Res"},{"key":"385_CR9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.7326\/M19-3827","volume":"173","author":"P Charles","year":"2020","unstructured":"Charles P, Perrodeau \u00c9, Samson M, et al. Long-term Rituximab Use to maintain remission of Antineutrophil cytoplasmic antibody\u2013Associated Vasculitis: a Randomized Trial. Ann Intern Med. 2020;173:179\u201387. https:\/\/doi.org\/10.7326\/M19-3827.","journal-title":"Ann Intern Med"},{"key":"385_CR10","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","volume":"75","author":"M Yates","year":"2016","unstructured":"Yates M, Watts RA, Bajema IM, et al. EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75:1583\u201394. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209133.","journal-title":"Ann Rheum Dis"},{"key":"385_CR11","unstructured":"Terrier B, Guillevin L. (2019) Protocole national de diagnostic et de soin des vascularites n\u00e9crosantes syst\u00e9miques (p\u00e9riart\u00e9rite noueuse et vascularites associ\u00e9es aux ANCA)."},{"key":"385_CR12","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1080\/21678707.2019.1701433","volume":"7","author":"J Sultana","year":"2019","unstructured":"Sultana J, Azzopardi-Muscat N, Coleiro B, et al. Pharmacological therapy in a rare disease: challenges in the long-term management of granulomatosis with polyangiitis. Expert Opin Orphan Drugs. 2019;7:521\u20133. https:\/\/doi.org\/10.1080\/21678707.2019.1701433.","journal-title":"Expert Opin Orphan Drugs"},{"key":"385_CR13","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","volume":"65","author":"P Tuppin","year":"2017","unstructured":"Tuppin P, Rudant J, Constantinou P, et al. Value of a national administrative database to guide public decisions: from the syst\u00e8me national d\u2019information interr\u00e9gimes de l\u2019Assurance Maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France. Rev D\u00c9pid\u00e9miologie Sant\u00e9 Publique. 2017;65:S149\u201367. https:\/\/doi.org\/10.1016\/j.respe.2017.05.004.","journal-title":"Rev D\u00c9pid\u00e9miologie Sant\u00e9 Publique"},{"key":"385_CR14","unstructured":"CNAM. (2021) M\u00e9thodologie m\u00e9dicale de la cartographie des pathologies et des d\u00e9penses, version G8 (ann\u00e9es 2015 \u00e0 2019, Tous R\u00e9gimes)."},{"key":"385_CR15","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus Azathioprine for maintenance in ANCA-Associated Vasculitis. N Engl J Med. 2014;371:1771\u201380. https:\/\/doi.org\/10.1056\/NEJMoa1404231.","journal-title":"N Engl J Med"},{"key":"385_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/5534851","volume":"2021","author":"KN Samman","year":"2021","unstructured":"Samman KN, Ross C, Pagnoux C, Makhzoum J-P. Update in the management of ANCA-Associated Vasculitis: recent developments and future perspectives. Int J Rheumatol. 2021;2021:1\u201314. https:\/\/doi.org\/10.1155\/2021\/5534851.","journal-title":"Int J Rheumatol"},{"key":"385_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13075-021-02452-8","volume":"23","author":"K Thomas","year":"2021","unstructured":"Thomas K, Argyriou E, Kapsala N, et al. Serious infections in ANCA-associated vasculitides in the biologic era: real-life data from a multicenter cohort of 162 patients. Arthritis Res Ther. 2021;23:90. https:\/\/doi.org\/10.1186\/s13075-021-02452-8.","journal-title":"Arthritis Res Ther"},{"key":"385_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/BOR.0000000000000348","volume":"29","author":"K Thomas","year":"2017","unstructured":"Thomas K, Vassilopoulos D. Infections and vasculitis. Curr Opin Rheumatol. 2017;29:17\u201323. https:\/\/doi.org\/10.1097\/BOR.0000000000000348.","journal-title":"Curr Opin Rheumatol"},{"key":"385_CR19","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3899\/jrheum.190065","volume":"47","author":"E Garcia-Vives","year":"2020","unstructured":"Garcia-Vives E, Segarra-Medrano A, Martinez-Valle F, et al. Prevalence and risk factors for major infections in patients with Antineutrophil cytoplasmic antibody\u2013associated Vasculitis: influence on the Disease Outcome. J Rheumatol. 2020;47:407\u201314. https:\/\/doi.org\/10.3899\/jrheum.190065.","journal-title":"J Rheumatol"},{"key":"385_CR20","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1007\/s00296-020-04661-x","volume":"40","author":"AE Caballero-Islas","year":"2020","unstructured":"Caballero-Islas AE, Hoyo-Ulloa I, Garc\u00eda-Castro A, Hinojosa-Azaola A. Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: a retrospective cohort study with a clinical phenotype approach. Rheumatol Int. 2020;40:1657\u201366. https:\/\/doi.org\/10.1007\/s00296-020-04661-x.","journal-title":"Rheumatol Int"},{"key":"385_CR21","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.advms.2020.01.002","volume":"65","author":"G Biedro\u0144","year":"2020","unstructured":"Biedro\u0144 G, W\u0142udarczyk A, Wawrzycka-Adamczyk K, et al. Treatment and its side effects in ANCA-associated vasculitides - study based on POLVAS registry data. Adv Med Sci. 2020;65:156\u201362. https:\/\/doi.org\/10.1016\/j.advms.2020.01.002.","journal-title":"Adv Med Sci"},{"key":"385_CR22","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1056\/NEJMoa1803537","volume":"382","author":"M Walsh","year":"2020","unstructured":"Walsh M, Merkel PA, Peh C-A, et al. Plasma exchange and glucocorticoids in severe ANCA-Associated Vasculitis. N Engl J Med. 2020;382:622\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1803537.","journal-title":"N Engl J Med"},{"key":"385_CR23","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1093\/rheumatology\/keaa070","volume":"59","author":"SH Sarica","year":"2020","unstructured":"Sarica SH, Dhaun N, Sznajd J, et al. Characterizing infection in anti-neutrophil cytoplasmic antibody\u2013associated vasculitis: results from a longitudinal, matched-cohort data linkage study. Rheumatology. 2020;59:3014\u201322. https:\/\/doi.org\/10.1093\/rheumatology\/keaa070.","journal-title":"Rheumatology"},{"key":"385_CR24","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1136\/annrheumdis-2013-203927","volume":"74","author":"J Robson","year":"2015","unstructured":"Robson J, Doll H, Suppiah R, et al. Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials. Ann Rheum Dis. 2015;74:177\u201384. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203927.","journal-title":"Ann Rheum Dis"},{"key":"385_CR25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s198-002-8341-z","volume":"13","author":"MM Boomsma","year":"2002","unstructured":"Boomsma MM, Stegeman CA, Kramer AB, et al. Prevalence of reduced bone mineral density in patients with anti-neutrophil cytoplasmic antibody associated vasculitis and the role of immunosuppressive therapy: a cross-sectional study. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2002;13:74\u201382. https:\/\/doi.org\/10.1007\/s198-002-8341-z.","journal-title":"Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA"},{"key":"385_CR26","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s00296-020-04631-3","volume":"40","author":"DG Fern\u00e1ndez-\u00c1vila","year":"2020","unstructured":"Fern\u00e1ndez-\u00c1vila DG, Rond\u00f3n-Carvajal J, Villota-Eraso C, et al. Demographic and clinical characteristics of patients with ANCA-positive vasculitis in a Colombian University Hospital over a 12-year period: 2005\u20132017. Rheumatol Int. 2020;40:1283\u201390. https:\/\/doi.org\/10.1007\/s00296-020-04631-3.","journal-title":"Rheumatol Int"},{"key":"385_CR27","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1002\/art.21117","volume":"52","author":"P Seo","year":"2005","unstructured":"Seo P, Min Y-I, Holbrook JT, et al. Damage caused by Wegener\u2019s granulomatosis and its treatment: prospective data from the Wegener\u2019s granulomatosis Etanercept Trial (WGET). Arthritis Rheum. 2005;52:2168\u201378. https:\/\/doi.org\/10.1002\/art.21117.","journal-title":"Arthritis Rheum"},{"key":"385_CR28","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1136\/annrheumdis-2016-209925","volume":"76","author":"EE van Daalen","year":"2017","unstructured":"van Daalen EE, Rizzo R, Kronbichler A, et al. Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. Ann Rheum Dis. 2017;76:1064\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209925.","journal-title":"Ann Rheum Dis"},{"key":"385_CR29","first-page":"S","volume":"33","author":"C Pagnoux","year":"2015","unstructured":"Pagnoux C, Carette S, Khalidi NA, et al. Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts. Clin Exp Rheumatol. 2015;33:S\u201377.","journal-title":"Clin Exp Rheumatol"},{"key":"385_CR30","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","volume":"77","author":"P Charles","year":"2018","unstructured":"Charles P, Terrier B, Perrodeau \u00c9, et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018;77:1143\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212878.","journal-title":"Ann Rheum Dis"},{"key":"385_CR31","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00296-019-04406-5","volume":"40","author":"L Corral-Gudino","year":"2020","unstructured":"Corral-Gudino L, Gonz\u00e1lez-V\u00e1zquez E, Calero-Paniagua I, et al. The complexity of classifying ANCA-associated small-vessel vasculitis in actual clinical practice: data from a multicenter retrospective survey. Rheumatol Int. 2020;40:303\u201311. https:\/\/doi.org\/10.1007\/s00296-019-04406-5.","journal-title":"Rheumatol Int"},{"key":"385_CR32","volume-title":"Adherence to long-term therapies: evidence for action","author":"E Sabat\u00e9","year":"2003","unstructured":"Sabat\u00e9 E, World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003."},{"key":"385_CR33","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s40674-021-00176-z","volume":"7","author":"C Pagnoux","year":"2021","unstructured":"Pagnoux C, Fifi-Mah A. Update on maintenance therapies for ANCA-Associated Vasculitis. Curr Treat Options Rheumatol. 2021;7:112\u201333. https:\/\/doi.org\/10.1007\/s40674-021-00176-z.","journal-title":"Curr Treat Options Rheumatol"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-024-00385-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-024-00385-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-024-00385-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T05:02:53Z","timestamp":1714280573000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcrheumatol.biomedcentral.com\/articles\/10.1186\/s41927-024-00385-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,28]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["385"],"URL":"https:\/\/doi.org\/10.1186\/s41927-024-00385-8","relation":{},"ISSN":["2520-1026"],"issn-type":[{"type":"electronic","value":"2520-1026"}],"subject":[],"published":{"date-parts":[[2024,4,28]]},"assertion":[{"value":"24 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The SNDS is a medico-administrative database of insured persons, and all patient-level data used for this retrospective analysis were collected as part of routine diagnosis and treatment. A unique anonymous identification number was associated to each insured person; as such, all data were fully anonymized prior to access and inclusion in this study. In accordance with the regulations in force, patient consent was not necessary because this study uses secondary data, there was a public interest in assessing the costs and clinical management of PID and SID patients in France, and the protection of patients\u2019 rights and freedom were guaranteed. The authorization to use the data was granted by the French data protection authority (Commission Nationale de l\u2019Informatique et des Libert\u00e9s, CNIL) (Decision DR-2019-009, and authorization No. 918434) and the study protocol obtained approval from the committee for research, studies, and evaluations in the field of health (Comit\u00e9 d\u2019expertise pour les recherches, les \u00e9tudes et les \u00e9valuations dans le domaine de la sant\u00e9, CEREES) (Decision TPS-235223).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Consent for publication: Not applicable.The study is based on secondary claims data and complied with regulations in force. Patient consent was not necessary. The persons concerned are informed of the implementation of the SNDS and the possible re-use of their personal health data in accordance with the procedures defined by Article R.1461-9 of the Public Health Code. The authorization to use the data was granted by the French data protection authority (Commission Nationale de l\u2019Informatique et des Libert\u00e9s, CNIL) (Decision DR-2019-009, and authorization No. 918434) and the study protocol obtained approval from the committee for research, studies, and evaluations in the field of health (Comit\u00e9 d\u2019expertise pour les recherches, les \u00e9tudes et les \u00e9valuations dans le domaine de la sant\u00e9, CEREES) (Decision TPS-235223). This study is a non-interventional study on pseudonymized data and does not involve humans (nor animals).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PMB reports support for the present manuscript from Vifor; Honoraria for lectures and board (personal fees) from Astellas, honoraria for lectures and board (personal fees) from Vifor; Support for attending meetings and\/or travel from Sanofi and Vifor; Participation on a Data Safety Monitoring Board or Advisory Board for Astellas and Vifor. C-AD reports support for the present manuscript from Vifor and support for attending meeting and\/or travel from Boehringer Ingelheim. DC has no conflict of interest to declare but support for the present manuscript from Vifor. AS reports working for HEVA, the company who carried out the study funded by Vifor. EST reports support for the present manuscript from Vifor; Grants or contracts from Astra Zeneca and Bayer; consulting fees from Bayer; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Astra Zeneca and support for attending meetings and\/or travel from Vifor and Amgen. BT reports consulting fees from Astra Zeneca, Vifor, and GlaxoSmithKline; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Astra Zeneca, Vifor, GlaxoSmithKline, and Boehringer Ingelheim and support for attending meetings and\/or travel from Vifor and GlaxoSmithKline.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}